Lilly's arzoxifene superior to Evista in osteoporosis
This article was originally published in Scrip
Executive Summary
Lilly has demonstrated that its investigational selective oestrogen receptor modulator (SERM) arzoxifene is superior to its older SERM Evista (raloxifene hydrochloride) in increasing bone mineral density (BMD) in postmenopausal women with osteoporosis in a Phase III study.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.